The inventor of Lyrica, one of Pfizer's biggest selling drugs, is looking for a CEO to lead an early-stage biotech company. AKAVA has been financed with several million dollars and houses multiple novel drugs for cancer and neuro indications. It is preclinical with the aim to file the IND by year-end and begin FIH dosing in 2H 2023.
The company is looking for an experienced biotech executive with an entrepreneurial spirit, strong communication/presentation skills, previous success bringing a drug through the clinic, and the ability and experience to raise significant capital ($20M+) to fund clinical operations. Experience transitioning to the public markets is also a plus. Compensation will have both a cash and equity component. If interested, please contact Drug Hunter
directly by replying to this e-mail with a description of your background and copy of your CV/resume.